University Hospital Schleswig-Holstein, Medical Clinic II, University Heart Center Lübeck, Lübeck, Germany.
DZHK (German Centre for Cardiovascular Research), Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany.
Clin Res Cardiol. 2023 May;112(5):633-644. doi: 10.1007/s00392-022-02150-8. Epub 2023 Jan 19.
The need for permanent pacemaker (PPM) implantation is a common complication after transcatheter aortic valve replacement (TAVR). Deep implantation position is a risk factor for PPM implantation. Thus, in the field of self-expandable (SE) transcatheter heart valves (THV) cusp overlap projection (COP) technique was implemented to reduce parallax, allowing a more precise guidance of implantation depth.
This meta-analysis aims to report the outcome of patients undergoing TAVR with SE THV using COP versus conventional implantation technique (CIT).
Systematical search in MEDLINE and EMBASE yielded five observational controlled studies comparing both implantation techniques for the SE Evolut prosthesis (Medtronic Intern. Ltd., CA, USA) and fulfilling the inclusion criteria for meta-analysis.
Totally, 1227 patients were included, comprising 641 who underwent COP and 586 CIT TAVR. Incidence of post-procedural need for PPM implantation was significantly lower in COP group (9.8% vs 20.6%; OR = 0.43; p < 0.00001). This was accompanied by significantly higher implantation position in COP group (mean difference distance from distal end of the intraventricular portion of the THV to the non-coronary cusp (NCC): - 1.03 mm; p = 0.00001). Incidence of new-onset left bundle branch block did not differ. Regarding procedural and 30-day mortality, technical success, post-procedural aortic regurgitation, and rates of multiple device implantation, no difference between COP and CIT was found.
COP is an effective and safe implantation technique to reduce the need for a permanent pacemaker implantation during TAVR with SE Evolut prosthesis.
经导管主动脉瓣置换术(TAVR)后需要植入永久性起搏器(PPM)是一种常见的并发症。植入位置过深是 PPM 植入的一个危险因素。因此,在自扩张(SE)经导管心脏瓣膜(THV)瓣叶重叠投影(COP)技术领域,采用该技术减少视差,以更精确地指导植入深度。
本荟萃分析旨在报告使用 COP 与传统植入技术(CIT)行 SE THV 的 TAVR 患者的结局。
在 MEDLINE 和 EMBASE 中进行系统检索,共纳入了 5 项比较 Evolut SE 瓣膜(美敦力国际有限公司,加利福尼亚州,美国)两种植入技术的观察性对照研究,这些研究均符合荟萃分析的纳入标准。
共纳入 1227 例患者,其中 COP 组 641 例,CIT 组 586 例。CO 组术后需要植入 PPM 的发生率明显低于 CIT 组(9.8%比 20.6%;OR=0.43;p<0.00001)。CO 组的植入位置明显更高(THV 心室段远端至非冠状动脉瓣叶的距离的平均差值(NCC):-1.03 毫米;p=0.00001)。新发左束支传导阻滞的发生率无差异。在手术和 30 天死亡率、技术成功率、术后主动脉瓣反流以及多器械植入率方面,COP 和 CIT 之间无差异。
在使用 SE Evolut 瓣膜行 TAVR 时,COP 是一种有效且安全的植入技术,可降低 PPM 植入的需求。